US Pharma MarketingParabilis Medicines charts $413M IPO to back peptide pipeline
If Parabilis follows through with its plans, that would make it one of the largest biotech IPOs of the past few years and the 12th biotech listing so far in 2026. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and…
Parabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut.
If the drug developer follows through with its plans, that ...
Source: Endpoints News